Hopkinton, MA and Alameda, CA —Caliper Life Sciences announced its S-4
filing for its acquisition of Xenogen (see IBO 2/15/06) was declared effective on July 11. Both companies will hold stockholder meetings on August 9 to vote on the acquisition. The acquisition, which is expected to close August 9, was originally scheduled to close in the second quarter. Due largely to this delay, Caliper has lowered its 2006 revenue guidance for $120–$128 million to $110–$118 million.